Management Strategies for Optimal Control of Anticoagulation in Patients with Atrial Fibrillation

Abstract

Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for prevention of thromboembolism, in particular ischemic stroke. Many studies show the efficacy of this treatment but also that it is difficult to keep patients who use vitamin K antagonists in the proper treatment range. Both a too low and a too high intensity of anticoagulation significantly increase the risk of adverse events. Hence repeated monitoring of the intensity of anticoagulation and dose adjustments are required. Management strategies that improve the time in the therapeutic target range are computer-assisted dosing algorithms and centralized care in anticoagulation clinics. In addition, self-testing of the international normalized ratio and self-dosing of vitamin K antagonists has been introduced over the past 20 years and has been shown to be an effective and safe treatment modality.

KEYWORDS

Anticoagulation - warfarin - coumarin - thrombosis - bleeding - atrial fibrillation

REFERENCES

• 1 Singer D E, Albers G W, Dalen J E et al.. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 546S-592S
• 2 Finsterer J, Stollberger C. Strategies for primary and secondary stroke prevention in atrial fibrillation.  Neth J Med. 2008;  66 327-333
• 3 Levi M, Hobbs F DR, Jacobson A K et al.. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives.  Semin Thromb Hemost. 2009;  527-542
• 4 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3 suppl) 204S-233S
• 5 Hart R G, Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.  Ann Intern Med. 1999;  131 492-501
• 6 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356 2301-2311
• 7 Levi M, Hovingh G K, Cannegieter S C, Vermeulen M, Buller H R, Rosendaal F R. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based.  Blood. 2008;  111 4471-4476
• 8 Hirsh J. Oral anticoagulant drugs.  N Engl J Med. 1991;  324 1865-1875
• 9 O'Reilly R A, Aggeler P M. Determinants of the response to oral anticoagulant drugs in man.  Pharmacol Rev. 1970;  22 35-96
• 10 Fairweather R B, Ansell J, van den Besselaar A M et al.. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.  Arch Pathol Lab Med. 1998;  122 768-781
• 11 Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 160S-198S
• 12 Geest-Daalderop J H, Hutten B A, Sturk A, Levi M M. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.  J Thromb Thrombolysis. 2003;  15 197-203
• 13 van Geest-Daalderop J H, Hutten B A, Pequeriaux N C, Haas F J, Levi M, Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol.  Thromb Haemost. 2007;  98 738-746
• 14 Kok G, Van Doben B, Mullen P D. Effectiveness of health education and health promotion: meta-analyses of effect studies and determinants of effectiveness.  Patient Educ Couns. 1997;  30 19-27
• 15 Beyth R J, Landefeld C S. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial.  J Gen Intern Med. 1997;  12 66
• 16 Horstkotte D, Piper C, Wiemer M, Schulte H D, Schultheiss H P. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy.  Eur Heart J. 1996;  17(suppl.) 230
• 17 Sawicki P T. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation.  JAMA. 1999;  281 145-150
• 18 Matchar D B, Samsa G P, Cohen S J, Oddone E Z, Jurgelski A E. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.  Am J Med. 2002;  113 42-51
• 19 Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.  Lancet. 1994;  343 687-691
• 20 van der Meer F J, Rosendaal F R, Vandenbroucke J P, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.  Arch Intern Med. 1993;  153 1557-1562
• 21 The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.  N Engl J Med. 1990;  323 1505-1511
• 22 Petersen P, Boysen G, Godtfredsen J, Andersen E D, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.  Lancet. 1989;  1 175-179
• 23 Cannegieter S C, Rosendaal F R, Wintzen A R, van der Meer F J, Vandenbroucke J P, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves.  N Engl J Med. 1995;  333 11-17
• 24 Ryan P J, Gilbert M, Rose P E. Computer control of anticoagulant dose for therapeutic management.  BMJ. 1989;  299 1207-1209
• 25 Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin.  J Clin Pathol. 1993;  46 299-303
• 26 Poller L, Shiach C R, MacCallum P K et al.. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.  Lancet. 1998;  352 1505-1509
• 27 Ageno W, Johnson J, Nowacki B, Turpie A G. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy.  Thromb Haemost. 2000;  83 849-852
• 28 van Geest-Daalderop J H, Hutten B A, Pequeriaux N C, Levi M, Sturk A. Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model.  J Thromb Thrombolysis. 2009;  27(2) 207-214
• 29 Cortelazzo S, Finazzi G, Viero P et al.. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic.  , [see comments] Thromb Haemost. 1993;  69 316-320
• 30 Errichetti A M, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic.  Arch Intern Med. 1984;  144 1966-1968
• 31 Ansell J E, Patel N, Ostrovsky D, Nozzolillo E, Peterson A M, Fish L. Long-term patient self-management of oral anticoagulation.  Arch Intern Med. 1995;  155 2185-2189
• 32 Palareti G, Leali N, Coccheri S et al.. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.  Lancet. 1996;  348 423-428
• 33 Fitzmaurice D A, Murray E T, Gee K M, Allan T F, Hobbs F D. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management.  J Clin Pathol. 2002;  55 845-849
• 34 Watzke H H, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.  Thromb Haemost. 2000;  83 661-665
• 35 van Es R F, Jonker J J, Verheugt F W, Deckers J W, Grobbee D E. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.  Lancet. 2002;  360 109-113
• 36 Levi M. Haemostasis and thrombosis: new developments in treatment strategies.  Neth J Med. 2003;  61 8-12
• 37 Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).  J Thromb Thrombolysis. 2007;  23 83-91
• 38 Nichol M B, Knight T K, Dow T et al.. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care.  Ann Pharmacother. 2008;  42 62-70
• 39 Leaning K E, Ansell J E. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management.  J Thromb Thrombolysis. 1996;  3 377-383
• 40 Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci P M. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy.  Thromb Haemost. 1997;  78 855-858
• 41 Kitchen S, Preston F E. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins.  J Clin Pathol. 1997;  50 951-956
• 42 Ansell J E. Empowering patients to monitor and manage oral anticoagulation therapy.  JAMA. 1999;  281 182-183
• 43 Levi M. Self-management of anticoagulation.  Expert Rev Cardiovasc Ther. 2008;  6 979-985
• 44 Fitzmaurice D A, Gardiner C, Kitchen S, Mackie I, Murray E T, Machin S J. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation.  Br J Haematol. 2005;  131 156-165
• 45 Oberhardt B J, Dermott S C, Taylor M, Alkadi Z Y, Abruzzini A F, Gresalfi N J. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis.  Clin Chem. 1991;  37 520-526
• 46 Kapiotis S, Quehenberger P, Speiser W. Evaluation of the new method CoaguChek for the determination of prothrombin time from capillary blood: comparison with Thrombotest on KC-1.  Thromb Res. 1995;  77 563-567
• 47 Machin S J, Mackie I J, Chitolie A, Lawrie A S. Near patient testing (NPT) in haemostasis—a synoptic review.  Clin Lab Haematol. 1996;  18 69-74
• 48 van den Besselaar A M, Breddin K, Lutze G et al.. Multicenter evaluation of a new capillary blood prothrombin time monitoring system.  Blood Coagul Fibrinolysis. 1995;  6 726-732
• 49 Cromheecke M E, Levi M, Colly L P et al.. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.  Lancet. 2000;  356 97-102
• 50 Matchar D B, Jacobson A K, Edson R G et al.. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481—the Home INR Study (THINRS).  J Thromb Thrombolysis. 2005;  19 163-172
• 51 Gadisseur A P, Breukink-Engbers W G, van der Meer F J, van den Besselaar A M, Sturk A, Rosendaal F R. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial.  Arch Intern Med. 2003;  163 2639-2646
• 52 Levi M, van der Meer F J, Cromheecke M E, de Mol B. Self-monitoring and self dosing of oral anticoagulant therapy with vitamin K antagonists.  Ned Tijdschr Geneeskd. 2001;  145 2313-2317
• 53 Gadisseur A P, Kaptein A A, Breukink-Engbers W G, van der Meer F J, Rosendaal F R. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life.  J Thromb Haemost. 2004;  2 584-591
• 54 Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial.  Thromb Haemost. 2007;  97 408-416
• 55 Siebenhofer A, Berghold A, Sawicki P T. Systematic review of studies of self-management of oral anticoagulation.  Thromb Haemost. 2004;  91 225-232
• 56 Heneghan C, Alonso-Coello P, Garcia-Alamino J M, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.  Lancet. 2006;  367 404-411
• 57 Sullivan P W, Arant T W, Ellis S L, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.  Pharmacoeconomics. 2006;  24 1021-1033
• 58 Anderson D R, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy.  Arch Intern Med. 1993;  153 1441-1447
• 59 Taborski U, Wittstamm F J, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany.  Semin Thromb Hemost. 1999;  25 103-108
• 60 Jowett S, Bryan S, Murray E et al.. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis.  Br J Haematol. 2006;  134 632-639
• 61 Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease.  J Thromb Thrombolysis. 1998;  5 S19-S24
• 62 Sidhu P, O'Kane H O. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients.  Ann Thorac Surg. 2001;  72 1523-1527
• 63 Hasenkam J M, Kimose H H, Knudsen L et al.. Self management of oral anticoagulant therapy after heart valve replacement.  Eur J Cardiothorac Surg. 1997;  11 935-942
• 64 Koertke H, Mainami K, Breymann T. INR self-management following mechanical heart valve replacement. Are education level and therapeutic compliance connected?.  J Thromb Thrombolysis. 2000;  9(suppl) S41-S46
• 65 Sunderji R, Gin K, Shalansky K et al.. A randomized trial of patient self-managed versus physician-managed oral anticoagulation.  Can J Cardiol. 2004;  20 1117-1123
• 66 Voller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).  Z Kardiol. 2005;  94 182-186
• 67 Eitz T, Schenk S, Fritzsche D et al.. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement.  Ann Thorac Surg. 2008;  85 949-954
• 68 White R H, McCurdy S A, von Marensdorff H, Woodruff Jr D E, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study.  Ann Intern Med. 1989;  111 730-737
• 69 Cosmi B, Palareti G, Carpanedo M et al.. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).  Haematologica. 2000;  85 826-831
• 70 Menendez-Jandula B, Souto J C, Oliver A et al.. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial.  Ann Intern Med. 2005;  142 1-10